Del Carmen Jeffrey's Form 4 filing
Catalyst Pharmaceuticals, Inc. (CPRX) · filed Nov 28, 2025
- Accession no.
- 0001161697-25-000430
- Filed
- Nov 28, 2025
- Trade date
- Nov 26, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $256.2K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Del Carmen JeffreyCIK 0001816477 | Officer (Chief Commercial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 26, 2025 | Common Stock, par value $0.001 per share | MOption exerciseAcquired | +10,983 | $4.21 | +$46,238.43 | 14,945 | Direct | |
| Nov 26, 2025 | Common Stock, par value $0.001 per share | SSaleDisposed | −10,983 | $23.33F1,F2 | −$256,233.39 | 3,962 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 26, 2025 | Common Stock | MOption exerciseAcquired | +10,983 | $0.00 | $0 | 1,053,552 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Shares were sold on the open market for personal reasons and not as a result of any disagreement with the Company.
Referenced by the price of 1 transaction in Table I.
- F2
Shares were sold in various lots from $23.331 to $23.345 per share. The price listed represents a weighted average price for the shares sold.
Referenced by the price of 1 transaction in Table I.